Physician & Nephrologist, MOH Malaysia.
Malaysia
Joined February 2020
- Tweets407
- Following259
- Followers98
- Likes73
Dr Chan Chee Eng retweeted
@sarah_gleeson_ tweeting from #ERAEDTA20 Claudio Ponticelli presenting on steroids in MCD, FSGS and IgA.
Reminder of steroid timing, dose changes and advice for patients.
Dr Chan Chee Eng retweeted
I really enjoyed the beautiful talk on FSGS at @GlomCon and the elegant work from @podocytes. Molecular signatures may be the future ancillary study to lead to precision diagnosis in multiple kidney diseases, including FSGS. Let's explore more. . . /1
Dr Chan Chee Eng retweeted
Repeat kidney biopsies in lupus nephritis! Relevant to dig underneath the tip of the iceberg? @smirioglu @AnnetteBruchfe1 @ERAkidney @StefanieSteige6 @LuvacsL
Dr Chan Chee Eng retweeted
Free Access: My 2026 update on diagnosis, risk stratification, treatment, and prognosis of multiple myeloma.
Link: onlinelibrary.wiley.com/doi/… @AjHematology
Algorithms. 10 Tables!
Bookmark!
Dr Chan Chee Eng retweeted
Curious how statistical experts assess this - stopped because of obvious treatment effect, but obviously almost crossed unity with a lower CI of 1.04!
Presented at #LIVES2026:
An open-label, randomized, noninferiority trial showed that intermittent hemodialysis was not noninferior to continuous renal-replacement therapy in critically ill adults with acute kidney injury. Full ICRAKI trial results: nej.md/472QMel
Editorial: Continuous or Intermittent Renal-Replacement Therapy — What is the Question? nej.md/4egLaB1
ALT A graph from the Original Article "Intermittent or Continuous Renal-Replacement Therapy in Acute Kidney Injury." The trial name, ICRAKI, is in parentheses after the title. The graph shows the cumulative probability of death from randomization through day 90, as estimated with the Kaplan–Meier method. The trial results are being presented at the European Society of Intensive Care Medicine. The logo of the New England Journal of Medicine is at the bottom.
Dr Chan Chee Eng retweeted
Plasma Exchange and Daratumumab for Myeloma Cast Nephropathy onlinelibrary.wiley.com/doi/… @kdjhaveri @Northwell_Med @ShrutiGkidney @AjHematology @onconephsociety @MGBKidneys @MayoClinicNeph
Dr Chan Chee Eng retweeted
Kidney biopsy findings in a patient treated with complement inhibitor-pegcetacoplan. First one for me.
Glomeruli appear and vacuolated and washed out. The vacuoles are most prominent in the podocytes.
The interstitium also contains vacuolated cells.
Glomeruli appear non proliferative and were negative for Ig and C3 on Immunofluorescence.
However, there was extensive global glomerulosclerosis and tubular atrophy and interstitial fibrosis.
Dr Chan Chee Eng retweeted
Ten tips for the diagnosis and management of nephrotic syndrome ca. 2026 from @CKJsocial
#Nephpearls
👉🏼 pubmed.ncbi.nlm.nih.gov/4270…
Dr Chan Chee Eng retweeted
Rituximab for relapsing nephrotic syndrome in adults: closing the evidence gap
doi.org/10.1093/ckj/sfag338
Dr Chan Chee Eng retweeted
De las mejores imágenes que resumen los tipos de daño en podocitopatías y su patrón histológico.
Paras clases de nefro !
😮😮😮🙌🏼🙌🏼🙌🏼
@DiseasePrimers – at Gustavo A. Madero, Distrito Federal
Dr Chan Chee Eng retweeted
We updated our Susztaklabbiobank website susztaklab.com
For almost two decades our laboratory has collected and profiled human kidney tissue, paired it with mouse and rat models and with the genetics of millions of people, and built one of the most complete maps of the human kidney that exists. This site is where we share it: genome-wide association results, expression, methylation, protein and open-chromatin maps, single-cell and single-nucleus atlases, spatial transcriptomes and animal-model resources, each in an interactive browser you can query today. Please send your suggestions how we could improve our site. Let's cure kidney disease together !
Dr Chan Chee Eng retweeted
Today we learned so much from the amazing Dr. Chebib @fouadchebib about risk stratification and prognosis in ADPKD at the @GlomCon #PKDMDP
Dr Chan Chee Eng retweeted
The why, what, who and when of B cell depletion in systemic lupus erythematosus: biological rationale, patient stratification and evolving therapeutic modalities
August 2026, keag416, doi.org/10.1093/rheumatology…
Published: 14 August 2026
Dr Chan Chee Eng retweeted
Complement in Kidney Disease: Core Curriculum 2026 - American Journal of Kidney Diseases ajkd.org/article/S0272-6386%…
Dr Chan Chee Eng retweeted
Very excited to share our new work in @jclinicalinvest!
How do anti-PLA2R autoantibodies (abs) actually cause podocyte injury in membranous nephropathy (MN)?
Great international collaboration with @KuChengLung @UKEHamburg & @HCKH_Hamburg.
jci.org/articles/view/191995
Dr Chan Chee Eng retweeted
🌍 Take your nephrology training further with an ISN Fellowship!
ISN membership opens the door to opportunities like the #ISNFellowship Program — helping you build your expertise, expand your network, and strengthen kidney care in your community.
Applications are open for physicians from lower-resource settings to gain specialized nephrology training and bring valuable skills back to their institutions.
🎓 800+ nephrologists from 100 countries supported since 1985.
📅 Apply by October 1: bit.ly/4gFBCQE
🔗 Join or renew your ISN membership and open the door to opportunities like this: bit.ly/4yfa4IS
#ThisIsISN #Nephrology
Dr Chan Chee Eng retweeted
Meet the 8 new members of the ISN Young Nephrologists Committee (ISN YNC)!
Get to know them, learn about their backgrounds, the challenges they face in their regions, and how they hope to contribute to the ISN YNC by reading the full article featuring an interview with each of them. ➡️ bit.ly/4xDiPwH
@ChanCheeEng2 @priti899 @hsugawara53 @NoraSarishvili
